Join
Live feed
·
PRReleasevia Quantisnow
Coya Therapeutics Inc. logo

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
COYA· Coya Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track COYA (Coya Therapeutics Inc.) and more on Quantisnow.